Middle East respiratory syndrome coronavirus: a comprehensive review

Mahmoud M. Shehata¹, Mokhtar R. Gomaa¹, Mohamed A. Ali¹, Ghazi Kayali (✉)²

¹Center of Scientific Excellence for Influenza Viruses, National Research Centre, Giza, Egypt; ²Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2016

Abstract The Middle East respiratory syndrome coronavirus was first identified in 2012 and has since then remained uncontrolled. Cases have been mostly reported in the Middle East, however travel-associated cases and outbreaks have also occurred. Nosocomial and zoonotic transmission of the virus appear to be the most important routes. The infection is severe and highly fatal thus necessitating rapid and efficacious interventions. Here, we performed a comprehensive review of published literature and summarized the epidemiology of the virus. In addition, we summarized the virological aspects of the infection and reviewed the animal models used as well as vaccination and antiviral tested against it.

Keywords MERS; coronavirus; review

Introduction

Coronaviruses (CoV) became known to cause human disease in the twentieth century. HCoV-229E and HCoV-OC43 were discovered in the 1960s and shown to cause respiratory infections in humans [1,2]. With the emergence of SARS-CoV in 2003 [3], two other human coronaviruses were discovered, HCoV NL63, HCoV HKU1 [4]. In 2012, a new type of coronavirus was detected as the cause of severe respiratory illness in humans. The first case was a 60-year-old male from Saudi Arabia admitted to hospital with acute respiratory illness leading to pneumonia and acute renal failure. The virus initially named as human coronavirus-EMC [5], is currently known as the Middle East respiratory syndrome coronavirus (MERS-CoV) [6].

Virology of MERS-CoV

Classification and nomenclature of MERS-CoV

Phylogenetically, MERS-CoV is a lineage C β coronavirus (β-CoV) and is closely related to bat coronaviruses HKU4 and HKU5. The rooted phylogenetic analysis showed that MERS-CoV had an amino acid sequence identity less than 90% to all other known CoVs [7]. The virus initially named by many different working groups as novel coronavirus, human coronavirus EMC, human β coronavirus 2c EMC, human β coronavirus 2c England-Qatar, human β coronavirus 2C Jordan-N3, and β coronavirus England 1, which represented the places where the first complete viral genome was sequenced (Erasmus Medical Center, Rotterdam, The Netherlands) or where the first laboratory-conﬁrmed cases were identiﬁed or managed (Jordan, Qatar, and England) was later named as MERS-CoV by the coronaviruses study groups of ICTV [5,6,8].

General virology of MERS-CoV

MERS-CoV is an enveloped virus with a positive sense RNA genome. Coronavirus genomes range between 25 to 32 kb in size. The complete sequence of HCoV-EMC-2012 resulted in 30 119 nucleotides sequence [7]. Coronavirus genomes are polycistronic with large replicase open reading frames ORF1a and ORF1b which are subsequently cleaved into 15 or 16 nonstructural proteins (NSPs). The region downstream of ORF1b encode smaller genes including the spike (S), envelope (E), membrane (M), and nucleocapsid (N) structural protein [9–11]. The functional receptor for MERS-CoV is the Dipeptidyl peptidase 4 (DPP4) which is present on human nonciliated bronchial epithelial cells surfaces [12]. The DPP4 protein displays high amino acid sequence conservation
across different species, including the sequence that was obtained from bat cells. Cell lines susceptibility studies showed that MERS-CoV infected several human cell lines, including histiocytes as well as respiratory, kidney, intestinal, and liver cells [13]. The range of tissue tropism in vitro was broader than that for any other known human coronavirus [14]. MERS-CoV can also infect nonhuman primate, porcine, bat, civet, rabbit, and horse cell lines all possessing the DPP4 receptor [15].

**MERS-CoV replication cycle**

The replication cycle of MERS-CoV consists of numerous steps as illustrated by Lu et al. [30].

**Viral receptor attachment**

The MERS-CoV S protein is a class I fusion protein composed of two subunits: the amino N-terminal receptor binding S1 and carboxyl C-terminal membrane fusion S2 subunits. The S1/S2 junction is a protease cleavage site which is responsible for membrane fusion activation, virus entry, and syncytium formation. The S1 C domain contains the receptor binding domain (RBD), and an N domain [13]. Neutralizing monoclonal antibodies against the RBD may inhibit virus entry into cells and receptor-dependent syncytium formation in cell culture, hence vaccines containing the RBD induced high levels of neutralizing antibodies in mice and rabbits [16–18].

DPP4 is the cell key functional receptor for the MERS-CoV S protein [19]. MERS-CoV is the first CoV that has been identified to use DPP4 as a receptor [19,20]. DPP4 has important roles in glucose metabolism, T cell activation, chemotaxis modulation, cell adhesion, and apoptosis [19,21].

**Membrane fusion**

The S2 subunit contains five domains: a fusion peptide, the heptad repeat 1 (HR1) and HR2 domains, a transmembrane domain, and a cytoplasmic domain, which form the stalk region of S protein that facilitates fusion of the viral and cell membranes [22,23]. The binding of the S1 subunit to the cellular receptor triggers conformational changes in the S2 subunit, which inserts its fusion peptide into the target cell membrane to form a six-helix bundle fusion core between the HR1 and HR2 domains that approximates the viral and cell membranes for fusion. MERS-CoV utilizes many pathways for membrane fusion depending on available host proteases, such as transmembrane protease serine protease 2 (TMPRSS2), trypsin, chymotrypsin, elastase, thermolysin, endoproteinase Lys-C, and human airway trypsin-like protease. Proteases cleave the S protein into the S1 and S2 subunits to activate the MERS-CoV S protein for endosome-independent host cell entry at the plasma membrane [24–26]. In addition to the previous fusion proteases furin has been identified recently to play an essential role in the MERS-CoV S protein cleavage activation into their biologically active forms [27,28].

**Disassembly, genome replication and expression**

After cell entry, the virion particle disassembles to release the nucleocapsid and viral RNA into the cytoplasm for expression of viral polyproteins pp1a and pp1ab. Double-membrane vesicles and convoluted membranes are formed by the attachment of the hydrophobic domains of the MERS-CoV replication machinery to the limiting membrane of auto-phagosomes [29]. The viral polyproteins pp1a and pp1ab are cleaved by papain-like protease and 3C-like protease into nsp1 to nsp16 [7,30,31]. These non-structural proteins form the replication-transcription complex, which regulates transcription and viral protein expression [29].

**Assembly and release of the new viruses**

After the production of abundant viral RNA and structural and accessory proteins, the N protein binds to the genomic RNA in the cytoplasm to form the helical nucleocapsid (viral core). The viral core is enveloped by budding through intracellular membranes between the endoplasmic reticulum and Golgi apparatus [32]. The S, E, and M proteins are transported to the budding virion, where the nucleocapsid probably interacts with M protein to generate the basic structure and complexes with the S and E proteins to induce viral budding and release from the Golgi apparatus [33]. MERS-CoV replication cycle is completed by releasing the progeny virions through the cell membrane via exocytosis pathway.

**Animal models for MERS-CoV infection**

**Mice**

MERS-CoV strain HCoV-EMC/2012 was inoculated to three different mouse strains (immunocompetent BALB/c mice, 129S6/SvEv and innate immune-deficient 129/STAT1−/− mice) intranasally. No significant weight loss was observed and infectious virus could not be detected in the lungs. Only moderate pathological lesions were observed in the lungs. Hence no viral replication was observed in these strains of mice [34].

Zhao et al. developed a mouse model transduced with a recombinant adenovirus vector expressing hDPP4 (Ad5-hDPP4) in lung tissue. Inoculation of MERS-CoV in these mice resulted in MERS-CoV replication but without mortality. Young mice cleared from MERS-CoV in 6–8 days and old mice in 10–14 days. Perivascular and
peribronchial lymphoid infiltration was observed, with progression to an interstitial pneumonia postinfection [35]. In another study, transgenic mice expressing hDPP4 were susceptible to MERS-CoV infection. Infectious virus was isolated from lung and brain tissue and weight loss was observed [36]. Pascal et al. developed humanized transgenic mouse. No mortality or clinical signs was observed but interstitial pneumonia and significant lung disease were observed histopathologically, suggesting that humanized DPP4 mouse is a model for MERS-CoV infection in which pathological changes resembles MERS-CoV infection in humans [37,38].

**Non-human primate models**

The rhesus macaque was the first animal model used for MERS-CoV infection as it possessed DPP4 receptor [38,39]. In infected animals, an increase in respiratory rates, body temperature, cough and reduced appetite was observed with mild to moderate severity. Infectious virus isolated only from the lower respiratory tract. Viral RNA was detected in the conjunctiva, nasal mucosa, tonsils, pharynx, trachea, bronchus and lungs. Mild to marked interstitial pneumonia with dark red lesions appeared in lungs. Seroconversion of neutralizing antibodies began at 7 dpi and increased in titer with time. The development of a transient pneumonia, rapid replication, and tropism of MERS-CoV for the lower respiratory tract resembled the severity of the disease observed in humans [38,40,41]. Similarly, the common marmoset was shown to possess the DPP4 receptor [42]. Radiographic imaging showed mild to severe bilateral interstitial infiltration and extensive bronchointerstitial pneumonia in infected animals. Infectious virus was detected in lower and upper respiratory tract tissue and viral RNA was detected in nasal mucosa, oropharyngeal swabs, blood, conjunctiva, lymph nodes, gastrointestinal tract, kidney, heart, adrenal gland, liver, spleen, brain and lungs [42].

**Other models**

Inoculation of Syrian hamsters and ferrets with MERS-CoV did not result in infection [12,43]. Rabbits may be used as a model to study pathogenesis, transmission, and disease control strategies of MERS-CoV *in vivo* as they seroconvert and shed virus after inoculation [44].

**Epidemiology of MERS-CoV**

In September 2012, a novel coronavirus infection was noted in ProMed Mail [45]. The virus was isolated from the sputum of a 60-year-old Saudi male, who was admitted to a hospital with pneumonia and acute kidney injury in June 2012. A few days later, another report appeared describing an almost identical virus detected in a patient in Qatar with acute respiratory syndrome and acute kidney injury. The patient had a recent travel history to Saudi Arabia and then traveled to UK for further medical care [5,46,47]. Two cases from Jordan (April 2012) were retrospectively diagnosed as MERS patients. Since that time, more than 1542 cases of MERS-CoV infection have been reported including 544 deaths [48]. The actual number of cases could be higher than those reported [49]. An outbreak of more than 180 confirmed cases including 36 deaths occurred in South Korea in May and June 2015. The median age of Korean cases were 55 years (range: 16 to 87 years), 60% were men, and 14% were health care professionals. The index case was a 68-year-old male who had recently traveled to several countries in the Arabian Peninsula [50].

**Case definitions, clinical manifestation, and diagnosis**

**Case definitions**

MERS-CoV infection cases were classified by the World Health Organization (WHO) [51], the US Centers for Disease Control and Prevention (CDC), and the Ministry of Health of Saudi Arabia (MOHSA) as asymptomatic, mild, severely symptomatic, or mortal. Cases may be classified into suspected, probable, and confirmed [52,53].

**Confirmed case**

Any person with laboratory confirmation of infection with MERS-CoV irrespective of clinical signs and symptoms is considered as a confirmed case. WHO criteria for laboratory confirmation require detection of viral RNA or acute and convalescent serology. The presence of nucleic acid can be confirmed by positive results from at least two sequence-specific rRT-PCRs or a single sequence-specific rRT-PCR test and direct sequencing from a separate genomic target [54]. A case confirmation by serological methods requires demonstration of seroconversion in two samples collected at least 14 days apart using at least one screening assay (enzyme-linked immunoassay, immunofluorescence assay) and a neutralization assay.

**Probable case**

A probable case is defined by the following criteria, a febrile acute respiratory illness as pneumonia or acute respiratory distress syndrome, direct contact with a confirmed MERS-CoV case and unavailability of MERS-CoV testing or results being inconclusive for a single inadequate specimen.
Suspected case

Any person who developed a fever and pneumonia or acute respiratory distress syndrome with a history of travel to countries in or near the Arabian Peninsula within 14 days before symptom onset or was in contact with a traveler from this region who developed a febrile respiratory illness is considered as a MERS-CoV suspected case.

Diagnosis

The WHO, CDC, and MOHSA recommended laboratory diagnostics for MERS-CoV infection [6,9,51,55,56]. MERS-CoV cases must be confirmed by at least two positive qRT-PCR tests on two different specific genomic regions or single positive qRT-PCR with a sequence of another positive genome fragment [57]. The WHO algorithm for testing MERS-CoV relies on qRT-PCR and sequencing [58]. Available real-time tests include an assay targeting the RNA upstream of the E gene (upE) as a highly sensitive screening assay and three confirmatory assays targeting open reading frames (ORF 1a and 1b) and/or N gene. The ORF 1a assay is of equal sensitivity to the upE assay. The ORF 1b assay is less sensitive but is useful for confirmation. These assays are specific for MERS-CoV and have not shown cross-reactivity with other respiratory human coronaviruses. For sequencing, two target genes, the RNA-dependent RNA polymerase (RdRp, present in ORF 1b) and N genes are enough to confirm the existence of MERS-CoV RNA in the samples of a patient [57].

Several serologic assays including immunofluorescence assays, protein microarray assay, enzyme-linked immunosorbent assay (ELISA) have been developed for the detection of MERS-CoV antibodies [57,59–61]. Any positive test by one of these assays should be confirmed with a neutralization assay. Single serological result may be valuable for definition of probable case and should be followed by further testing for confirmation of MERS-CoV infection [62–64].

Clinical manifestation of MERS-CoV infection

Incubation period of MERS-CoV infections was studied by Assiri et al. in 2013. The median incubation period was 5.2 days (95% CI 1.9–14.7 days) [65]. In another report from France of a secondary case, a patient who shared a room with an infected patient, the incubation period was estimated at 9 to 12 days [66]. In the recent outbreak in South Korea during May/June 2015, the median incubation period was 6.3 days [67]. WHO and CDC recommended that individuals that returned from the Arabian Peninsula and other affected countries must be evaluated for MERS-CoV infections up to at least 14 days [68].

Clinical features of MERS-CoV infections range from asymptomatic cases to mildly ill, severe pneumonia, acute respiratory distress syndrome, septic shock and mortal with multi-organ failure (Table 1) [64,65]. Many other clinical features such as gastrointestinal symptoms (anorexia, nausea, vomiting, abdominal pain, diarrhea), pericarditis, and disseminated intravascular coagulation were reported [65,69,70].

Specific clinical conditions (comorbidities) were apparently proportionate with high severity of MERS-CoV infections. A study by Assiri et al. in Saudi Arabia showed that of a total of 47 patients with MERS-CoV infection in 2013, 45 (96%) had underlying clinical conditions, including diabetes mellitus (68%), hypertension (34%), chronic cardiac disease (28%), and chronic kidney disease (49%) [65]. This high rate of comorbidities must be interpreted with some caution, since diabetes mellitus is common in Saudi Arabia, and because approximately half of those 47 were part of an outbreak in a hemodialysis unit, where rates of comorbidities might be high due to chronic kidney disease [65,71]. In another study, being on dialysis, diabetes mellitus, and age > 50 years was associated with mortality [72]. In this study, testing positive for MERS-CoV in a plasma sample was a predictor of severe outcome [72].

Younger adults and children appeared to be less susceptible to MERS-CoV infection. Only one study described MERS-CoV infection in children [73]. All of those children were discovered during contact investigations of older patients. Only 2 of 11 children developed symptoms of MERS-CoV infection. These two children had underlying conditions (cystic fibrosis and Down syndrome). The other 9 children were asymptomatic. There are few reports of MERS-CoV infections in pregnant women. A five-month pregnant female developed vaginal bleeding and abdominal pain after one week, then delivered a stillborn infant [74]. Another case in the United Arab Emirates was near term phase, she gave birth to an apparently healthy baby, and died after delivery [52].

Mild and asymptomatic MERS-CoV infections have been reported, a majority of whom were identified among the contacts of patients [62,75,76]. In a report from MOHSA, more than 3000 contacts of patients were screened using qRT-PCR and seven healthcare workers with MERS-CoV infection were identified, two of whom were asymptomatic and five of whom had mild upper respiratory tract symptoms [75].

Human-to-human transmission

Epidemiological and virological studies were conducted in attempts to determine person to person transmission of MERS-CoV. They studied case clustering in household and hospital outbreaks in the UK, Tunisia, Italy, and in healthcare facilities in Saudi Arabia, France, Iran, and lately in South Korea. Those studies provided strong evidence that human-to-human transmission occurs
The number of contacts infected by individuals with confirmed infections, however, appears to be limited [62], except the outbreak of South Korea in May/June 2015, where most cases were secondary and some cases were tertiary infections [67,81]. Secondary cases often were milder or symptomless [62]. Possible modes of transmission include droplet and close contact transmission, air borne transmission, and fomite transmission [82].
The majority of all laboratory-confirmed secondary cases have been associated with healthcare settings [82]. The majority of cases of Jeddah, Saudi Arabia hospital outbreak during the spring of 2014 were acquired through human-to-human transmission due to systematic weaknesses in infection control [76]. Secondary transmission rates were assessed within households and the transmission rate was around 4%, suggesting that the actual number of infection is greater than reported [62].

During the outbreak in South Korea during May/June 2015, 25 secondary infections were associated with the index case, who was hospitalized from May 15 to May 17 and 11 were tertiary [83]. The median incubation period was six days for secondary cases and six days for tertiary cases. This outbreak also clearly demonstrated roles of “superspreaders,” who may be responsible for a high proportion of cases [83]. For instance, a single patient infected more than 70 other people while being treated in the emergency room of a hospital in South Korea for three days, 27–29 May 2015.

Transmissibility and epidemic potential studies of MERS-CoV revealed that the reproduction number (R0) of patients infected with MERS-CoV ranged between 0.6 to 0.69 [84,85]. The finding of an R0 < 1 suggests that MERS-CoV does not yet have pandemic potential. Other study suggested that R0 values might reach to 0.8 to 1.3 in the absence of infection control [49]. Shedding periods of MERS-CoV in humans was reported to be long as viruses were detected in lower respiratory samples of symptomatic patients for more than two weeks [86]. At instances, prolonged shedding for 6 weeks was detected in an asymptomatic healthcare worker. These findings raise concerns that asymptomatic persons could transmit infection to others in a silent manner [87].

**Geographic distribution of MERS-CoV cases**

The majority of cases have occurred in Saudi Arabia and United Arab Emirates [88–90]. Many cases have also been reported outside the Arabian Peninsula in North Africa, Europe, Asia, and North America as shown in Table 2. Almost all cases reported outside the Arabian Peninsula had a travel history to it.

**Notable outbreaks and clusters**

The first cluster was in October/November 2012 in four men of the same family in Riyadh, Saudi Arabia, two of whom died [75]. The second cluster was reported in Jordan in April 2012 involving 10 healthcare workers exposed to fatal patients. In addition, seven surviving hospital contacts seroconverted suggesting that they had MERS-CoV infection [91]. The third cluster was reported in UK during January/February 2013. An English resident had a travel history to Saudi Arabia and Pakistan in January, developed a severe respiratory illness, and tested positive for both MERS-CoV and H1N1 influenza A, and died in March 2013 after infecting several contacts [92]. A cluster of 43 cases of MERS-CoV was reported in Al-Hasa in Saudi Arabia during April 2013. All those cases were directly linked to human to human contact in the same hospital. There were only two confirmed cases of healthcare workers, and three family members were detected by a survey of over 200 household contacts that visited this hospital [77]. In France, May 2013, an infection of MERS-CoV was reported in a patient who recently traveled to the United Arab Emirates. A second case who shared the hospital room with the first case tested positive. The first patient died and the second patient was critically ill. A survey of 100 healthcare workers found no other infections with MERS-CoV, despite the lack of use of personal protective equipment [70].

A surge in MERS-CoV cases was reported in Saudi Arabia and the United Arab Emirates during March and April 2014 [55,76]. The majority of cases were associated with hospital-based outbreaks Jeddah, Riyadh, Tabuk, and Madinah in Saudi Arabia as well as in Al Ain, and Abu Dhabi in United Arab Emirates. Cases included several healthcare workers, visitors, patients, and ambulance staff. Person to person transmission was confirmed in > 75% of cases. The majority of infected health care workers developed mild symptomatic or asymptomatic infection, but about 15% had severe illness or died [93].

The recent outbreak of South Korea occurred in May 2015. The index case was a man who had recently traveled to Bahrain, the United Arab Emirates, Saudi Arabia, and Qatar [55]. As of late July 2015, > 180 secondary cases were reported including 36 death and many cases had been reported among household and hospital contacts [55,67]. In China, one case occurred in a man who traveled to China from Korea following exposure to two relatives with MERS-CoV infection [55].

**Disease seasonality**

In spite of reporting of MERS-CoV infections throughout the year, some evidence on disease seasonality occurred. The first identified cases of MERS-CoV infection were reported in April and June 2012 [5,46,47]. A high increase in cases was reported in April and May 2013 followed by a surge in case reporting in April and May 2014. Increase in case reporting in March to May 2013 were attributed to infection from infected young camels [94,95], but the increase in 2014 in Saudi Arabia and in South Korea in 2015 were due to gaps in infection control in hospitals. Small peaks in case reporting occurred in September and November of 2013 and 2014. The epicurve of infection is shown in Fig. 1.
Zoonotic origin of MERS-CoV

Role of bats

Sources and modes of transmission of MERS-CoV are still unclear. Initially, a bat origin of MERS-CoV was suggested based on the relation of genome sequences between MERS-CoV and bat coronaviruses [96]. Cell tropism studies showed that both bat coronavirus HKU4 and MERS-CoV shared the same cell type receptors, DPP4 [4,7,75]. MERS-CoV grows readily in several bat-derived cell lines [14]. There is no evidence for direct or indirect transmission of MERS-CoV from bats to humans. Virological studies performed in Europe, Africa, and Asia, including the Middle East, have shown that coronavirus RNA sequences are found frequently in bat feces. Some of the sequences were closely related to MERS-CoV sequences [97–99]. In a survey from Saudi Arabia, 823 fecal and rectal samples were tested by PCR for MERS-CoV, many coronavirus sequences were detected [97]. Most of the detected sequences were unrelated to MERS-CoV, but one sequence of 190 nucleotide in the RNA-dependent RNA polymerase (RdRp) gene had a 100% identity with a MERS-CoV. This sequence was detected from feces of a Taphozous perforatus bat captured near the home of the index Saudi patient. Uncommon contact of humans with bats indicates that bats are not the intermediate host of MERS-CoV transmission but may be the reservoir of the virus [100].

Role of camels

Dromedary camels (Camelus dromedarius) appear to be the source of MERS-CoV. Other animals like sheep, goats, and cows tested negative to anti-MERS-CoV antibodies. Camel sera from Oman, Canary Islands, and Egypt were positive for anti-MERS-CoV antibodies in about 100%, 14%, and > 90% of the samples respectively [63,101, 102]. Retrospective studies on archived human sera showed no evidence of infection with MERS-CoV before 2012 [103], but anti-MERS-CoV antibodies were detected

---

Table 2 Number of MERS-CoV by country as of July 7, 2015 as per WHO data

| Country         | 2012 | 2013 | 2014 | 2015 | Total |
|-----------------|------|------|------|------|-------|
| Algeria         | 0    | 0    | 2    | 0    | 2     |
| Austria         | 0    | 0    | 1    | 0    | 1     |
| China           | 0    | 0    | 0    | 1    | 1     |
| Egypt           | 0    | 0    | 1    | 0    | 1     |
| France          | 0    | 2    | 0    | 0    | 2     |
| Germany         | 1    | 1    | 0    | 1    | 3     |
| Greece          | 0    | 0    | 1    | 0    | 1     |
| Iran            | 0    | 0    | 5    | 1    | 6     |
| Italy           | 0    | 1    | 0    | 0    | 1     |
| Jordan          | 2    | 0    | 10   | 0    | 12    |
| Kuwait          | 0    | 2    | 1    | 0    | 3     |
| Lebanon         | 0    | 0    | 1    | 0    | 1     |
| Malaysia        | 0    | 0    | 1    | 0    | 1     |
| Netherlands     | 0    | 0    | 2    | 0    | 2     |
| Oman            | 0    | 1    | 1    | 4    | 6     |
| Philippines     | 0    | 0    | 0    | 2    | 2     |
| Qatar           | 0    | 7    | 2    | 4    | 13    |
| South Korea     | 0    | 0    | 0    | 185  | 185   |
| Saudi Arabia    | 5    | 136  | 679  | 210  | 1037  |
| Thailand        | 0    | 0    | 0    | 1    | 1     |
| Tunisia         | 0    | 3    | 0    | 0    | 3     |
| Turkey          | 0    | 0    | 1    | 0    | 1     |
| United Arab Emirates | 0   | 12   | 57   | 7    | 76    |
| UK              | 1    | 3    | 0    | 0    | 4     |
| USA             | 0    | 0    | 2    | 0    | 2     |
| Yemen           | 0    | 0    | 1    | 0    | 1     |
| Total           | 9    | 168  | 768  | 413  | 1368  |
in archived camel sera in Saudi Arabia in 1993 [95], and United Arab Emirates in 2003 [104], indicating circulation of MERS-CoV in camels for many years. Bactrian camels in Mongolia tested negative for MERS-CoV antibodies [105].

Serologic studies from around the Middle East suggested that camels are one of the sources of MERS-CoV as > 90% of adult camels tested positive and had high titers of antibodies. Seropositivity was different in juvenile camels and was usually lower than in adults. These results suggested that MERS-CoV infections in camels occurred in young ages followed by frequent boosting [94,95,102,104]. Camels in other parts of the world, far from the Middle East like in Europe, Australia, and the Americas do not have MERS-CoV antibodies and have no evidence of infection [106]. Table 3 summarizes camel serologic studies.

In a study aimed to evaluate virus infectivity and shedding in camels, three adult dromedary camels were inoculated with MERS-CoV intratracheally, intranasally, and conjunctivally. Those camels shed large quantities of virus from the upper respiratory tract and infectious virus was detected in nasal secretions for 7 days post-inoculation and viral RNA for up to 35 days post-inoculation [113].

Human infections with MERS-CoV were linked to camels. The first evidence was a study in Saudi Arabia in which the MERS-CoV full genome sequences of isolates from a man with fatal infection and from one of his camels were identical. This patient had a direct contact with his deceased camels some days before the onset of symptoms. These results suggested that MERS-CoV can infect dromedary camels and can be transmitted from them to humans by direct close contact [86]. In other studies, phylogenetic analyses of camel and human isolates of the MERS-CoV genome demonstrated that the viruses were highly identical or in some cases were similar to each other [107,108,114].

Seroepidemiological studies shown low prevalence of MERS-CoV antibodies in humans in Saudi Arabia [103,115]. A survey of 10 009 individuals representative of the general population of Saudi Arabia resulted in 15 seropositive subjects (0.15%), however, seropositivity increased 15–23 folds in camel-exposed individuals [78]. In a separate report, 7 of 87 camel shepherds and 140 slaughterhouse workers (3.1%) tested positive for MERS-CoV antibodies [103]. An overview of MERS-CoV transmission routes is illustrated in Fig.2.

**Vaccines and antivirals**

**Vaccines**

The development of an effective vaccine is critical for prevention of a MERS-CoV pandemic. Some investigators have indicated that the RBD protein of MERS-CoV S protein is a good candidate antigen as a subunit vaccine. Various RBD fragments showed the highest DPP4 binding affinity and induced the highest-titer of IgG Ab and neutralizing Ab in mice and rabbits [17,18,116–120]. A
A robust neutralizing antibody response was elicited in BALB/c mice against MERS-CoV after immunization with purified full S protein nanoparticles produced in Sf9 cells infected with specific recombinant baculovirus containing the S gene [121] or a recombinant human adenoviral vectors (rAd5 or rAd41) containing the S or S1 genes [122,123]. Vaccinia Ankara was encoded with full S protein and inoculated to BALB/c mice that developed high levels of neutralizing antibodies and had induction of humoral and cell-mediated immunity [124,125]. Another study using Ad5-hDPP4-transduced BALB/c mice immunized with Venezuelan equine encephalitis virus replicon particles containing S protein elucidated a reduction of viral titers to nearly undetectable levels and increased neutralizing antibodies [35].

Recently, Wang et al. developed two candidate vaccines, a subunit (full S and S1 protein fraction) and a DNA vaccine (full S and S1 gene in a mammalian VRC8400 vector). The vaccine containing the full S DNA and S1 protein was the most efficacious in mice and rhesus macaques [126].

**Passive immunization**

Using antibodies to deter MERS-CoV infection appears to have some promise. Transfer of sera containing anti-MERS-CoV-S protein to or seropositive camel sera to Ad5-hDPP4-transduced mice accelerated virus clearance, inhibited virus attachment, and reduced weight loss [35,37,127]. Recently, Corti et al. successfully isolated monoclonal antibodies from serum obtained from a MERS-CoV survivor after 200 days of infection [128]. Transduced Ad5-hDPP4 BALB/c mice were immunized with 15 mg/kg of the mAb and showed decreased lung

### Table 3  Serological studies in camels

| Study location | Sampling time | Sample size | Test name                          | Animal species | Seropositive percentage | Camel age          | Reference |
|---------------|---------------|-------------|------------------------------------|----------------|-------------------------|--------------------|-----------|
| Oman          | 2013          | 50          | Protein microarray, neutralization test | Dromedary      | 100                     | Adult              | [102]     |
| Canary Islands| 2013          | 195         | Protein microarray, neutralization test | Dromedary      | 14                      | Adults and one juvenile | [102]     |
| Egypt         | 2013          | 110         | Pseudoparticle, neutralization assay | Dromedary      | 94                      | Adult              | [63]      |
| Egypt         | 2013          | 52          | Pseudoparticle, neutralization assay | Dromedary      | 92.3                    | Adult              | [107]     |
| Egypt, Sudan, Somalia | 1983–1997   | 43          | ELISA, neutralization test         | Dromedary      | 81.4                    | Not available      | [106]     |
| Qatar         | 2013          | 14          | Neutralization assay               | Dromedary      | 100                     | Not mentioned      | [108]     |
| Saudi Arabia  | 2010–2013     | 310         | Pseudoparticle, neutralization assay | Dromedary      | 90                      | 27 juveniles, 283 adults | [109]     |
| Saudi Arabia  | 2014          | 9           | Immunofluorescence assay           | Dromedary      | 22.2                    | 6 adults, 3 juveniles | [73]      |
| UAE           | 2005          | 151, 500    | Spike protein microarray            | Dromedary      | 81.8                    | Adult              | [104]     |
| USA, Canada   | 2000–2001     | 6           | Neutralization assay               | Dromedary      | 0                       | Adult              | [110]     |
| Ethiopia      | 2010–2011     | 188         | Protein microarray                 | Dromedary      | 96                      | 1-13 years         | [111]     |
| Nigeria       | 2010–2011     | 358         | Protein microarray                 | Dromedary      | 94                      | Adult              | [111]     |
| Jordan        | 2013          | 11          | Protein microarray, neutralization test | Dromedary      | 100                     | Juvenile           | [101]     |
| Tunisia       | 2010–2011     | 204         | Protein microarray                 | Dromedary      | 48.5                    | 1-16 years         | [111]     |
| Sudan         | 1983          | 60          | ELISA, neutralization test         | Dromedary      | 86.7                    | Adult              | [106]     |
| Somalia       | 1983, 1984    | 25, 61      | ELISA, neutralization test         | Dromedary      | 80, 85.2                | Adult              | [106]     |
| Kenya         | 1993–2013     | 774         | ELISA                             | Dromedary      | 27.5                    | Not mentioned      | [112]     |
| Australia     | 2014          | 25          | Pseudoparticle, neutralization assay | Dromedary      | 0                       | Adults and juvenile | [95]      |
| Mongolia      | 2015          | 200         | Pseudoparticle, neutralization test | Dromedary      | 0                       | Adults and juvenile | [105]     |
viral titers, no weight loss, and decreased peribronchial lymphoid infiltration [128].

**Antivirals**

No approved antivirals for use against MERS-CoV infection are yet available. The first approach performed when a new unknown virus like MERS-CoV emerges is testing drugs used as antiviral for similar viruses [29,129,130]. Type I interferons and ribavirine combination exhibited acceptable results in cell culture and rhesus macaques by decreasing the host inflammatory response, replication of virus, and improved clinical outcome [129,131,132]. A human cohort study in Saudi Arabia showed that treatment with combination of ribavirin and interferon-α2b to 5 did not improve clinical outcomes but this may have been due to late treatment or due to the immunocompromised state of the patients [133]. In a retrospective study of 20 MERS-CoV infected patients treated with ribavirin and interferon α-2a, results showed 14-day and 28-day survival was improved by 70% and 28% in the treated group as compared to an untreated group [134].

The second approach is screening of approved drugs with known safety profiles and transcriptional signatures in different cell lines. Several drugs, including antiparasitics, neurotransmitters, antibacterials, inhibitors of clathrin-mediated endocytosis estrogen receptor, lipid or sterol metabolism, protein processing, and DNA synthesis or repair were tested on culture cells [119,135–139]. Lopinavir-ritonavir combined with pegylated interferon and ribavirin therapy showed improved outcomes in infected marmosets [140].

The third approach involves *in vitro* inhibition of S protein to block virus entry into host cells using designed antiviral peptides targeting the HR2 domain of the S2 subunit of the MERS-CoV and preventing the interaction between the HR1 and HR2 domains required for the formation of the heterologous six-helix bundle in viral fusion core formation [22,23]. Other drugs that act as inhibitors for viral proteases and helicase to suppress MERS-CoV infection were tested [141–145]. Other investigators studied inhibition of MERS-CoV infection by competitive inhibition of DPP4 cell receptor using compounds such as sitagliptin, vildagliptin, and saxagliptin [19,146].

**Conclusions**

More than three years have passed since the first detection of MERS-CoV human infection and the virus, uncontrollable, continues to cause major outbreaks in the Middle East. The recent outbreak in Korea demonstrated that a single index case can lead to 185 more infections in a short period of time, hence raising questions about the accuracy of the number of cases being reported in the Middle East. Furthermore, the Korean outbreak confirmed the high fatality rate of MERS-CoV infection as being true rather
than overestimated in case only the more severe cases are detected. In all, public health, veterinary health, and research efforts need to be consolidated in order to answer the following high priority questions:

- What is the true extent of human infection with MERS-CoV?
- What antivirals and vaccines are to be used in humans?
- What infection control measures are needed in healthcare settings to prevent nosocomial outbreaks?
- What measures need to be in place in order to prevent zoonotic infections from camels?
- Is it possible to control the virus in the camel population and if so, how?
- Are there other animal species involved in the MERS-CoV transmission cycle?

Acknowledgements

This work was funded by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract number HHSN272201400006C, the Egyptian Science and Technology Development Fund, under contract number 5175, and supported by the American Lebanese Syrian Associated Charities (ALSAC).

Compliance with ethics guidelines

Mahmoud M. Shehata, Mokhtar R. Gomaa, Mohamed A. Ali, and Ghazi Kayali declare that they have no conflict of interest. This manuscript is a review article and does not involve a research protocol requiring approval by the relevant institutional review board or ethics committee.

References

1. Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 1966; 121(1): 190–193
2. McIntosh K, Dees JH, Becker WB, Kapikian AZ, Chanock RM. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci USA 1967; 57(4): 933–940
3. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, Nicholls J, Yee WK, Yan WW, Cheung MT, Cheng VC, Chan KH, Tsang DN, Yung RW, Ng TK, Yuen KY; SARS study group. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361(9366): 1319–1325
4. Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, Bai R, Teng JL, Tsang CC, Wang M, Zheng BJ, Chan KH, Yuen KY. Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol 2012; 86(7): 3995–4008
5. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012; 367(19): 1814–1820
6. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LL, Snijder EJ, Stephens GM, Woo PC, Zaki AM, Zambon M. Ziebuhr J. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol 2013; 87(14): 7790–7792
7. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE, Snijder EJ, Fouchier RA. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012; 3(6): e00473-12
8. Cotten M, Watson SJ, Kellam P, Al-Rabeeah AA, Makhdoum HQ, Assiri A, Al-Tawfiqu JA, Alhakeem RF, Madani H, AlRabiah FA, Al Hajjar S, Al-nassir WN, Albarak A, Flenbman H, Balthy HH, Alsulabi S, Palser AL, Gall A, Bashford-Rogers R, Rambaut A, Zumla AI, Memish ZA. Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. Lancet 2013; 382(9909): 1993–2002
9. Bialek SR, Allen D, Alvarado-Ramy F, Arthur R, Balaje A, Bell D, Best S, Blackmore C, Breakwell L, Cannons A, Brown C, Cetron M, Chea N, Chommanard C, Cohen N, Conover C, Crespo A, Crevison J, Cums AT, Dahl R, Dearth S, DeMaria A, Echols F, Erdman DD, Feikin D, Frias M, Gerber SI, Gulati R, Hale C, Haynes LM, Heberlein-Larson L, Holton K, Ijaz K, Kapoor M, Kohl K, Kuhar DT, Kumar AM, Kundich M, Lippold S, Liu L, Lovchik JC, Madoff L, Martell S, Matthews S, Moore J, Murray LR, Onofrey S, Pallansch MA, Pesik N, Pham H, Pillai S, Pontones P, Pringle K, Pritchard S, Rasmussen S, Richards S, Sandoval M, Schneider E, Schuchat A, Sheedy K, Sherin K, Swerdlow DL, Tappero JW, Vernon MO, Watkins S, Watson J; Centers for Disease Control and Prevention (CDC). First confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in the United States, updated information on the epidemiology of MERS-CoV infection, and guidance for the public, clinicians, and public health authorities—May 2014. MMWR Morb Mortal Wkly Rep 2014; 63(19): 431–436
10. Gorbalenya AE, Enjuanes L, Ziebuhr J, Snijder EJ. Coronaviruses: evolving the largest RNA virus genome. Virus Res 2006; 117(1): 17–37
11. Ziebuhr J, Snijder EJ, Gorbalenya AE. Virus-encoded proteasomes and proteolytic processing in the Coronaviridae. J Gen Virol 2000; 81 (Pt 4): 853–879
12. Raj VS, Smits SL, Provacia LB, van den Brand JM, Wiersma L, Rottier PJ, Fouchier RA, Bosch BJ, Osterhaus AD, Haagmans BL, Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4-mediated entry of the Middle East respiratory syndrome coronavirus. J Virol 2013; 87(14): 7792–7796
13. Cheng VC, Chen H, Che XY, Lau SK, Woo PC, Yuen KY. The Middle East respiratory syndrome coronavirus 2c EMC/2012: implications for disease pathogenesis and clinical manifestation. J Infect Dis 2013; 207(11): 1743–1752
14. Müller MA, Raj VS, Muth D, Meyer B, Kallies S, Smits SL, Wollny R, Bestebroer TM, Specht S, Suliman T, Zimmermann K,
Mahmoud M. Shehata et al.

Binger T, Eckerle I, Tschapka M, Zaki AM, Osterhaus AD, Fouchier RA, Haagmans BL, Drosten C. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. MBio 2012; 3(6): e00515-12.

15. Meyer B, García-Bocanegra I, Wernery U, Wernery R, Sieberg A, Müller MA, Drexler JF, Drosten C, Eckerle I. Serologic assessment of possibility for MERS-CoV infection in equids. Emerg Infect Dis 2015; 21(1): 181–182.

16. Du L, Zhao G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Wang L, Debnath AK, Zheng BJ, Zhou Y, Jiang S. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013; 87(17): 9939–9942.

17. Mou H, Raj VS, van Kuppeveld FJ, Rottjer PJ, Haagmans BL, Bosch BJ. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013; 87(16): 9379–9383.

18. Ma C, Wang L, Tao X, Zhang N, Yang Y, Tseng CT, Li F, Zhou Y, Jiang S, Du L. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—the importance of immunofocusing in subunit vaccine design. Vaccine 2014; 32(46): 6170–6176.

19. Raj VS, Mou H, Smits SL, Dekkers DH, Müller MA, Dijkman R, Muth D, Demmers JA, Zaki A, Fouchier RA, Thiel V, Drosten C, Rottjer PJ, Osterhaus AD, Bosch BJ, Haagmans BL. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus EMCoV. Nature 2013; 495(7440): 251–254.

20. Chan JF, To KK, Tse H, Jin DY, Yuen KY. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol 2013; 21(10): 544–555.

21. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidylpeptidase IV from bench to bedside: an update on structural biology and its importance of immunofocusing in subunit vaccine design. Vaccine 2014; 32(46): 6170–6176.

22. Lu L, Liu Q, Du L, Wang L, Yang G, Kou Z, Ma C, Sun S, Poon VK, Lu L, Zhao G, Zheng BJ, Zhou Y, Jiang S. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013; 21(1): 181–182.

23. Gao J, Lu G, Qi L, Li Y, Wu Y, Deng Y, Geng H, Li H, Wang Q, Xiao H, Tan W, Yan J, Gao GF. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol 2013; 87(24): 13134–13140.

24. Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Krämer-Kühl A, Welsch K, Winkler M, Meyer B, Drosten C, Dittrmer U, von Hahn T, Simmons G, Hofmann H, Pöhlmann S. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013; 87(10): 5502–5511.

25. Gierer S, Müller MA, Heurich A, Ritz D, Springstein BL, Karsten CB, Schenkelzeltor A, Grünf K, Drosten C, Pöhlmann S. Inhibition of proprotein convertases abrogates processing of the middle eastern respiratory syndrome coronavirus spike protein in infected cells but does not reduce viral infectivity. J Infect Dis 2015; 211(6): 889–897.

26. Qian Z, Domínguez SR, Holmes KV. Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PLoS ONE 2013; 8(10): e76469.

27. Milliet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci USA 2014; 111(42): 15214–15219.

28. Thomas G. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 2002; 3(10): 753–766.

29. de Wilde AH, Raj VS, Oudshoorn D, Bestebroer TM, van Nieuwkoop S, Limpens RW, Posthuma CC, van der Meer Y, Bércena M, Haagmans BL, Snijder EJ, van den Hoogen BG. MERS-coronavirus replication induces severe in vivo cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. J Gen Virol 2013; 94(10): 1749–1760.

30. Lu L, Liu Q, Du L, Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect 2013; 15(8-9): 625–629.

31. Lei J, Mesters JR, Drosten C, Anemüller S, Ma Q, Hilgenfeld R. Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features. Antiviral Res 2014; 109: 72–82.

32. Nanayanan K, Maeda A, Maeda J, Makino S. Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells. J Virol 2000; 74(17): 8127–8134.

33. Studler K, Masignani V, Eickmann M, Becker S, Abruñagui S, Klenk HD, Rappuoli R. SARS—beginning to understand a new virus. Nat Rev Microbiol 2003; 1(3): 209–218.

34. Coleman CM, Matthews KL, Goicochea L, Frieman MB. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol 2014; 95(3): 408–412.

35. Zhao J, Li K, Way H-T, Benveniste C, Aghihothram SS, Fett C, Zhao J, Gale MJ Jr, Baric RS, Enjuanes L, Gallagher T, McCray PB Jr, Perlman S. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014; 111(13): 4970–4975.

36. Agrawal AS, Garron T, Tao X, Peng BH, Waksay M, Chan TS, Couch RB, Tseng CT. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 2015; 89(7): 3659–3670.

37. Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, Hunt C, Strein J, Berrebi A, Sisk JM, Matthews KL, Babb R, Chen G, Lai KM, Huang TT, Olson W, Yancopoulos GD, Stahl N, Frieman MB, Kyratsous CA. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci USA 2015; 112(28): 8738–8743.

38. Munster VJ, de Wit E, Hendriksen S. Pneumonia from human Middle East respiratory syndrome coronavirus (MERS-CoV). N Engl J Med 2013; 368(16): 1560–1562.

39. van Doremalen N, Miazgowicz KL, Milne-Price S, Bushmaker T, Robertson S, Scott D, Kinne J, McLellan JS, Zhu J, Munster VJ. Host species restriction of Middle East respiratory syndrome coronavirus.
coronavirus through its receptor, dipeptidyl peptidase 4. J Virol 2014; 88(16): 9220–9232
40. de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL, Fischer ER, Martellaro C, Okumura A, Chang J, Scott D, Benecke AG, Katze MG, Feldmann H, Munster VJ. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci USA 2013; 110(41): 16598–16603
41. Yao Y, Bao L, Deng W, Xu L, Li F, Lv Q, Yu P, Chen T, Xu Y, Zhu H, Yuan J, Gu S, Wei Q, Chen H, Yuen KY, Qin C. An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J Infect Dis 2014; 209(2): 236–242
42. Falzarano D, de Wit E, Rasmussen AL, Okumura A, Peng X, Thomas MJ, van Doremalen N, Haddock E, Nagy L, LaCasse R, Liu T, Zhu J, McLellan JS, Scott DP, Katze MG, Feldmann H, Munster VJ. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog 2014; 10(8): e1004250
43. de Wit E, Prescott J, Baseler L, Bushmaker T, Thomas T, Lackemeyer MG, Martellaro C, Milne-Price S, Haddock E, Haagmans BL, Feldmann H, Munster VJ. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS ONE 2013; 8(7): e69127
44. Haagmans BL, van den Brand JM, Provacia LB, Raj VS, Stittelaar KJ, Getu S, de Waal L, Bestebroer TM, van Amerongen G, Verjans GM, Fouchier RA, Smits SL, Kuiken T, Osterhaus AD. Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits. J Virol 2015; 89(11): 6131–6135
45. ProMed-Mail: Novel coronavirus—Saudi Arabia: human isolate. Archive Number: 20120920.1302733. Published Date: 2012-09-20
46. Wise J. Patient with new strain of coronavirus is treated in intensive care at London hospital. BMJ 2012; 345: e6455
47. WHO. Novel coronavirus infection in the United Kingdom. 2012
48. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV)—Saudi Arabia. August 21, 2015. Available from: www.who.int/csr/don/21-august-2015-mers-saudi-arabia/en/. Accessed August 25, 2015
49. Cauchemez S, Fraser C, Van Kerkhove MD, Donnelly CA, Riley S, Rambaut A, Enouf V, van der Werf S, Ferguson NM. Middle East respiratory syndrome coronavirus: quantification of the extent of the epidemic, surveillance biases, and transmissibility. Lancet Infect Dis 2014; 14(1): 50–56
50. WHO. MERS-CoV in the Republic of Korea at a glance. 2015
51. WHO. Laboratory testing for Middle East respiratory syndrome coronavirus — Interim recommendations (revised). 2014
52. WHO. Revised case definition for reporting to WHO—Middle East respiratory syndrome coronavirus—Interim case definition as of 14 July 2014. 2014
53. CDC. Middle east respiratory syndrome (MERS), case definition. 2015
54. WHO. Middle East respiratory syndrome coronavirus, case definition for reporting to WHO, interim case definition as of 14 July 2015. 2015
55. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV): summary of current situation, literature update and risk assessment. 2015
56. CDC. Interim guidelines for collecting, handling, and testing clinical specimens from patients under investigation (PUIs) for Middle East respiratory syndrome coronavirus (MERS-CoV). 2014; Version 2.1
57. Corman VM, Müller MA, Costabel U, Timm J, Binger T, Meyer B, Kreher P, Lattwein E, Eschbach-Blandau M, Nitsche A, Bleicker T, Landt O, Schweiger B, Drexler JF, Osterhaus AD, Haagmans BL, Dittmer U, Bonif B, Wolff T, Drosten C. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveill 2012; 17(49): 20334
58. WHO. Laboratory testing for Middle East respiratory syndrome coronavirus. 2014
59. Chan KH, Chan JF, Tse H, Chen H, Lau CC, Cai JP, Tsang AK, Xiao X, To KK, Lau SK, Woo PC, Zheng BJ, Wang M, Yuen KY. Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J Infect 2013; 67(2): 130–140
60. Buchholz U, Müller MA, Nitsche A, Sanewski A, Weverning N, Bauer-Balci T, Bonin F, Drosten C, Schweiger B, Wolff T, Muth D, Meyer B, Buda S, Krause G, Schaadene L, Haas W. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill 2013; 18(8): 20406
61. Reusken C, Mou H, Godeke GJ, van der Hoek L, Meyer B, Müller MA, Haagmans B, de Sousa R, Schuurman N, Dittmer U, Rottier P, Osterhaus A, Drosten C, Bosch BJ, Koopmans M. Specific serology for emerging human coronaviruses by protein microarray. Euro Surveill 2013; 18(14): 20441
62. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri M, Hossain R, Madani H, Sieberg A, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, Hajomar W, Albarrak AM, Al-Tawfiq JA, Zumla AI, Memish ZA. Transmission of MERS-coronavirus in household contacts. N Engl J Med 2014; 371(9): 828–835
63. Perera RA, Wang P, Gomaa MR, El-Shesheny R, Kandeil A, Bagato O, Siu LY, Shehata MM, Kayed AS, Moatasim Y, Li M, Poon LL, Guan Y, Webbly RJ, Ali MA, Peiris JS, Kayali G. Seroepidemiology for MERS coronavirus using monoclonal and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill 2013; 18(36): 20574
64. WHO. Laboratory testing for Middle East respiratory syndrome coronavirus. 2013
65. Assiri A, Al-Tawfiq JA, Al-Rabieeh AA, Al-Rabieh FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, Makhdoom HQ, Zumla AI, Memish ZA. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13(9): 752–761
66. Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina B, Caro V, Campese C, Guéry B, Prouvost H, Lemaire X, Paty MC, Haeghebaert S, Antoine D, Ettafan N, Noel H, Behillil S, Hendrix S, Manuguerra JC, Enouf V, La Ruche G, Semaillé C, Coignard B, Lévy-Bruhl D, Weber F, Saura C, Che D. Investigation Team. First cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infections in France, investigations and implications for the
prevention of human-to-human transmission, France, May 2013. Euro Surveill 2013; 18(24): 20502
67. Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill 2015; 20(25): 21163
68. CDC. Update: severe respiratory illness associated with Middle East respiratory syndrome coronavirus (MERS-CoV)—worldwide, 2012–2013. 2013
69. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabaeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 2013; 368(26): 2487–2494
70. Guery B, Poissy J, el Mansouf L, Séjourné C, Ettahar N, Lemaire X, Votto F, Goffard A, Béhilil S, Enouf V, Caro V, Mailles A, Che D, Manuguerra JC, Mathieu D, van der Werf S; MERS-CoV Study Group. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission. Lancet 2013; 381(9885): 2265–2272
71. Drosten C. Is MERS another SARS? Lancet Infect Dis 2013; 13(9): 727–728
72. Shallhoub S, Farahat F, Al-Jiftiri A, Simhairi O, Siddiqi N, Mustaqa A. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 2015; 70(7): 2129–2132
73. Memish ZA, Al-Tawfiq JA, Assiri A, AlRabiah FA, Al Hajjar S, AlBarrak A, Flebhan H, Alhakeem RF, Makhdoom HQ, Alsulabaie S, Al-Rabaeah AA. Middle East respiratory syndrome coronavirus disease in children. Pediatr Infect Dis J 2014; 33(9): 904–906
74. Payne DC, Iblan I, Alqasrawi S, Al Nsour M, Rha B, Tohme RA, Abedi GR, Farag NH, Haddadin A, Al Sanhouri T, Jarour N, Sverdlov DL, Jamieson DJ, Pallansch MA, Haynes LM, Gerber SI, Al Abdallat MM; Jordan MERS-CoV Investigation Team. Sabri N, Al Azhari M, Khazali H, Al Maayah M, Bilbeisi A, Swerdlow DL, Jamieson DJ, Mathieu D, Fontanet A, van der Werf S; MERS-CoV Study Group. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission. Lancet 2013; 381(9885): 2265–2272
75. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Sanouri T, Tamin A, Harcourt JL, Kuhar DT, Swerdlow DL, Al-Gethamy M, Corman VM, Hussain R, Al-Tawfiq JA, Memish ZA. A case of long-term excretion and subclinical infection with Middle East respiratory syndrome coronavirus. J Infect Dis 2014; 209(12): 1870–1872
76. Memish ZA, Zumla AI, Assiri A. Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med 2013; 369(9): 848–886
77. Obobo IK, Tomczyk SM, Al-Ammari AM, Banjar AA, Al-Mugri H, Aloraini MS, Alkhaldi KZ, Almohamadi EL, Alraddadi BM, Gerber SI, Sverdlov DL, Watson JT, Madani TA. 2014 MERS-CoV outbreak in Jeddah—a link to health care facilities. N Engl J Med 2015; 372(9): 846–854
78. Assiri A, McGear A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al-Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla AI, Memish ZA; KSA MERS-CoV Investigation Team. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369(5): 407–416
79. Müller MA, Meyer B, Corman VM, Al-Masri M, Turkestani A, Ritz D, Sieberg A, Alldabbagh S, Bosch BJ, Lattwein E, Alhakeem RF, Assiri AM, Albarrak AM, Al-Shangiti AM, Al-Tawfiq JA, Wikramaratna P, Alrabeeah AA, Drosten C, Memish ZA. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis 2015; 15(6): 629
80. Abroug F, Slim A, Ouanes-Besbes L, Hadj Kacem MA, Dachraoui F, Ouanes I, Lu X, Tao Y, Paden C, Caidi H, Miao C, Al-Hajri MM, Zorraqa M, Ghaouar W, Ben Salah A, Gerber SI; World Health Organization Global Outbreak Alert and Response Network Middle East Respiratory Syndrome Coronavirus International Investigation Team. Family cluster of Middle East respiratory syndrome coronavirus infections, Tunisia, 2013. Emerg Infect Dis 2014; 20(9): 1527–1530
81. WHO. Summary and risk assessment of current situation in South Korea as of 5 February 2015. 2015
82. Bauch CT, Oraby T. Assessing the pandemic potential of MERS-CoV. Lancet 2013; 382(9939): 694–699
83. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM, Madani TA. Evidence for camel-to-human transmission of MERS-CoV. N Engl J Med 2014; 370(26): 2499–2505
84. Al-Gethamy M, Corman VM, Hussain R, Al-Tawfiq JA, Drosten C, Memish ZA. A case of long-term excretion and subclinical infection with Middle East respiratory syndrome coronavirus in a healthcare worker. Clin Infect Dis 2015; 60(6): 973–974
85. Raha B, Rudd J, Feinkin D, Watson J, Curns AT, Sverdlov DL, Pallansch MA, Gerber SI; Centers for Disease Control and Prevention (CDC). Update on the epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) infection, and guidance for the public, clinicians, and public health authorities—January 2015. MMWR Morb Mortal Wkly Rep 2015; 64(3): 61–62
86. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; 386(9997): 995–1007
87. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV): summary of current situation, literature update and risk assessment—as of 5 February 2015. 2015
88. Al-Abdallat MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, Al Nsour M, Iblan I, Jarour N, Farag NH, Haddadin A, Al-Sanouri T, Tamin A, Harcourt JL, Kuhar DT, Sverdlov DL, Erdman DD, Pallansch MA, Haynes LM, Gerber SI; Jordan MERS-CoV Investigation Team. Sabri N, Al Azhari M, Khazali H, Al Maayah M, Bilbeisi A, Dawood N, Al Zubi B, Meffli J, Mounds T, Fitzner J, Eltom A, Mafa A, Miao C, Caidi H, Trivedi S,
Kamili S, Hall AJ, Curns A, Moore J, Pham H, Zimmerman C, Farnon E, Giorgi G, Gerber R. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 2014; 59 (9): 1225–1233

92. Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C, Hoschler K, Brown K, Galiano M, Myers R, Pebody RG, Green HK, Boddington NL, Gopal R, Price N, Newsholme W, Drosten C, Foucher RA, Zambon M. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill 2012; 17(40): 20290

93. WHO. WHO risk assessment. Middle East respiratory syndrome coronavirus (MERS-CoV). 2014

94. Hemida MG, Chu DK, Poon LL, Perera RA, Alhajri MM, Ng HY, Siu LY, Guan Y, Alnaeem A, Peiris M. MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerg Infect Dis 2014; 20 (7): 1231–1234

95. Hemida MG, Perera RA, Al Jassim RA, Kayali G, Siu LY, Wang P, Chu KW, Perlman S, Ali MA, Alnaeem A, Guan Y, Poon LL, Saif L, Peiris M. Seroenpidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. Euro Surveill 2014; 19(23): 20828

96. Corman VM, Ithete NL, Richards LR, Schoeman MC, Preiser W, Drosten C, Drexler JF. Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterisation of a conspecific virus from an African bat. J Virol 2014; 88(19): 11297–11303

97. Memish ZA, Mishra N, Olival KJ, Fogbo SF, Kapoor V, Epstein JH, Alhakeem R, Durosinloun A, Al Asmari M, Islam A, Kapoor A, Briese T, Dassak P, Al Rabeeah AA, Lipkin WI. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013; 19(11): 1819–1823

98. Annan A, Baldwin HJ, Corman VM, Klose SM, Owusu M, Nkrumah EE, Badu EK, Anti P, Agbenyega O, Meyer B, Oppong S, Sarkodie YA, Kalko EK, Lina PH, Godlevska EV, Reusken CB, Nowotny N, van Maanen K, Hidalgo-Hermoso E, Bosch BJ, Rottier P, Osterhaus A, Gortázar-Schmidt C, Drosten C, Koopmans MP. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 2013; 13(10): 859–866

99. Aburizaiza AS, Mattes FM, Azhar EI, Hassan AM, Memish ZA, Muth D, Meyer B, Latthein E, Müller MA, Drosten C. Investigation of anti-middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012. J Infect Dis 2014; 209(2): 243–246

100. Meyer B, Müller MA, Corman VM, Reusken CB, Ritd D, Godeke GJ, Latthein E, Kallies S, Siemens A, van Beek J, Drexler JF, Muth D, Bosch BJ, Wernery U, Koopmans MP, Wernery R, Drosten C. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis 2014; 20(4): 552–559

101. Chan SM, Damdinjav B, Perera RA, Chu DK, Khishgee B, Enkholdb B, Poon LL, Peiris M. Absence of MERS-Coronavirus in Bactrian Camels, Southern Mongolia, November 2014. Emerg Infect Dis 2015; 21(7): 1269–1271

102. Miller MA, Corman VM, Jores J, Meyer B, Younau M, Lijander A, Bosch BJ, Latthein E, Hilali M, Musa BE, Bornstein S, Drosten C. MERS coronavirus neutralizing antibodies in camels, Eastern Africa, 1983–1997. Emerg Infect Dis 2014; 20(12): 2093–2095

103. Hemida MG, Perera RA, Wang P, Alhammadi MA, Siu LY, Guan Y, Alnaeem A, Peiris M, Kayali G. MERS coronaviruses in dromedary camels, Egypt. Emerg Infect Dis 2014; 20(6): 1049–1053

104. Haagmans BL, Al Dhahiry SH, Reusken CB, Raj VS, Galiano M, Myers R, Godeke GJ, Jonges M, Farag E, Diab A, Ghobashy H, Alhajri F, Al Thani M, Al Marri SA, Al Romaihi HE, Al Khal A, Bermingham A, Osterhaus AD, Al Hajri MM, Koopmans MP. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 2014; 14(2): 140–145

105. Hemida MG, Perera RA, Wang P, Alhammadi MA, Siu LY, Li M, Poon LL, Saif L, Alnaeem A, Peiris M. Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill 2013; 18(50): 20659

106. Alexandersen S, Kohberg GP, Soule G, Wernery U. Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005. Transbound Emerg Dis 2014; 61(2): 105–108

107. Reusken CB, Messadi L, Feyisa A, Ullarum H, Godeke GJ, Danmarwa A, Dawo F, Jemli M, Melaku S, Shamaki D, Woma Y, Wungak Y, Gebremedhin EZ, Zutt I, Bosch BJ, Haagmans BL, Koopmans MP. Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg Infect Dis 2014; 20(8): 1370–1374
114. Alagaili AN, Briese T, Mishra N, Kapoor V, Sameroff SC, Burbelo PD, de Wit E, Munster VJ, Hensley LE, Zalmout IS, Kapoor A, Epstein JH, Karesh WB, Daszak P, Mohammed OB, Lipkin WI. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio 2014; 5(2): e00884–e14
115. Gierer S, Hofmann-Winkler H, Albuali WH, Bertram S, Al-Rubaish AM, Youssef AA, Al-Nafiai AN, Al-Ali AK, Obeid OE, Alkaharsah KR, Pöhlmann S. Lack of MERS coronavirus neutralizing antibodies in humans, eastern province, Saudi Arabia. Emerg Infect Dis 2013; 19(12): 2034–2036
116. Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, Zhou Y, Du L, Jiang S. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 2014; 32(18): 2100–2108
117. Jiang L, Wang N, Zuo T, Shi X, Poon KM, Wu Y, Gao F, Li D, Wang R, Guo J, Fu L, Yuen KY, Zheng BJ, Wang X, Zhang L. Potential neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014; 6(234): 234ra59
118. Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, Chen Y, Yu F, Tseng CT, Zhou Y, Jiang S. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS ONE 2013; 8(12): e81587
119. Zhao G, Du L, Ma C, Li Y, Li L, Poon VK, Wang L, Yu F, Zheng BJ, Jiang S, Zhou Y. A safe and convenient pseudovirus-based infection assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J 2013; 10(1): 266
120. Lan J, Deng Y, Chen H, Lu G, Wang W, Guo X, Lu Z, Gao GF, Tan W. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS ONE 2014; 9(11): e112602
121. Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, Glenn GM, Smith GE, Frieman MB. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014; 32(26): 3169–3174
122. Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A. Immune-logicity of an adenosineviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice. Vaccine 2014; 32(45): 5975–5982
123. Guo X, Deng Y, Chen H, Lan J, Wang W, Zou X, Hung T, Lu Z, Tan W. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology 2015; 145(4): 476–484
124. Song F, Fux R, Provacia LB, Volz A, Eickmann M, Becker S, Osterhaus AD, Haagmans BL, Sutter G. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing anti-bodies. J Virol 2013; 87(21): 11950–11954
125. Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, Schmidt J, Becker C, Eickmann M, Becker S, Sutter G. Protective efficacy of recombinant Modified Vaccinia virus Ankara (MVA) delivering Middle East Respiratory Syndrome coronavirus spike glycoprotein. J Virol 2015; 89(16): 8651–8656
126. Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyi M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagni U, Solomon J, Mollura DJ, Hensley L, Jahlring P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 2015; 6: 7712
127. Zhao J, Perera RA, Kayali G, Meyerholz D, Perlman S, Peiris M. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Virol 2015; 89(11): 6117–6120
128. Corti D, Zhao J, Pedotti M, Simonelli L, Agnihothram S, Fett C, Fernandez-Rodriguez B, Foglietini M, Agatic G, Vanzetta F, Gopal R, Laprish CJ, Barrett NA, Saltustio F, Baric RS, Varani L, Zambon M, Perlman S, Lanza vecchia A. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci USA 2015; 112(33): 10473–10478
129. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep 2013; 3: 1686
130. Frausto SD, Lee E, Tang H. Cyclophilins as modulators of viral replication. Viruses 2013; 5(7): 1684–1701
131. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, Yuen KY. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67(6): 606–616
132. Falzarano D, de Wit E, Rasmussen AL, Feldmann F, Okumura A, Scott DP, Brining D, Bus hmaker T, Martellaro C, Baseler L, Benecke AG, Katze MG, Munster VJ, Feldmann H. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013; 19(10): 1313–1317
133. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014; 20: 42–46
134. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaaradoor YS, Almakhafi LA, Albarrak MM, Memish ZA, Albarrak AM. Ribavirin and interferon α-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 2014; 14(11): 1090–1095
135. Josset L, Menachery VD, Gralinski LE, Agnihothram S, Sova P, Carter VS, Yount BL, Graham RL, Baric RS, Katze MG. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio 2013; 4(3): e00165–e13
136. Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MB, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, Olinger GG, Hensley LE, Jahlring PB. Antiviral potential of ERK/MAPK and
PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother 2015; 59(2): 1088–1099

137. Liu Q, Xia S, Sun Z, Wang Q, Du L, Lu L, Jiang S. Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother 2015; 59(1): 742–744

138. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, van den Hoogen BG, Neyts J, Snijder EJ. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 2014; 58(8): 4875–4884

139. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG Jr, Frieman MB, Holbrook MR, Jahrling PB, Hensley L. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2014; 95(Pt 3): 571–577

140. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, Li F, Xiao C, Gao H, Yu P, Cai JP, Chu H, Zhou J, Chen H, Qin C, Yuen KY. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 2015; 212(12): 1904–1913

141. Wu A, Wang Y, Zeng C, Huang X, Xu S, Su C, Wang M, Chen Y, Guo D. Prediction and biochemical analysis of putative cleavage sites of the 3C-like protease of Middle East respiratory syndrome coronavirus. Virus Res 2015; 208: 56–65

142. Kilianski A, Mielech AM, Deng X, Baker SC. Assessing activity and inhibition of Middle East respiratory syndrome coronavirus papain-like and 3C-like proteases using luciferase-based biosensors. J Virol 2013; 87(21): 11955–11962

143. Adeleji AO, Singh K, Kassim A, Coleman CM, Elliott R, Weiss SR, Frieman MB, Sarafianos SG. Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses. Antimicrob Agents Chemother 2014; 58(8): 4894–4898

144. Cheng KW, Cheng SC, Chen WY, Lin MH, Chuang SJ, Cheng IH, Sun CY, Chou CY. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res 2015; 115: 9–16

145. Ren Z, Yan L, Zhang N, Guo Y, Yang C, Lou Z, Rao Z. The newly emerged SARS-like coronavirus HCoV-EMC also has an “Achilles’ heel”: current effective inhibitor targeting a 3C-like protease. Protein Cell 2013; 4(4): 248–250

146. Ohnuma K, Haagmans BL, Hatano R, Raj VS, Mou H, Iwata S, Dang NH, Bosch BJ, Morimoto C. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol 2013; 87(24): 13892–13899